11/29
03:35 am
tvtx
Travere Therapeutics (NASDAQ:TVTX) was downgraded by analysts at
Wall St
Low
Report
Travere Therapeutics (NASDAQ:TVTX) was downgraded by analysts at
Wall St
11/28
08:00 am
tvtx
Travere Therapeutics (NASDAQ:TVTX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $47.00 price target on the stock.
Medium
Report
Travere Therapeutics (NASDAQ:TVTX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $47.00 price target on the stock.
11/26
08:18 am
tvtx
Why IBD 50's No. 3 Stock, Travere Therapeutics, Has Doubled In 2025 [Yahoo! Finance]
Low
Report
Why IBD 50's No. 3 Stock, Travere Therapeutics, Has Doubled In 2025 [Yahoo! Finance]
11/26
07:22 am
tvtx
Travere Therapeutics: Thriving Kidney Franchise Set To Soar On January PDUFA [Seeking Alpha]
Low
Report
Travere Therapeutics: Thriving Kidney Franchise Set To Soar On January PDUFA [Seeking Alpha]
11/19
03:00 pm
tvtx
Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally [Yahoo! Finance]
Low
Report
Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally [Yahoo! Finance]
11/14
07:54 am
tvtx
Travere Therapeutics (NASDAQ:TVTX) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Medium
Report
Travere Therapeutics (NASDAQ:TVTX) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
11/10
05:00 pm
tvtx
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/6
11:29 am
tvtx
Travere Therapeutics Announces Late-Breaking Data from Phase 3 DUPLEX Study of FILSPARI in FSGS Presented at the American Society of Nephrology (ASN) Kidney Week 2025 [Yahoo! Finance]
Neutral
Report
Travere Therapeutics Announces Late-Breaking Data from Phase 3 DUPLEX Study of FILSPARI in FSGS Presented at the American Society of Nephrology (ASN) Kidney Week 2025 [Yahoo! Finance]
11/6
11:00 am
tvtx
Travere Therapeutics Announces Late-Breaking Data from Phase 3 DUPLEX Study of FILSPARI in FSGS Presented at the American Society of Nephrology (ASN) Kidney Week 2025
Low
Report
Travere Therapeutics Announces Late-Breaking Data from Phase 3 DUPLEX Study of FILSPARI in FSGS Presented at the American Society of Nephrology (ASN) Kidney Week 2025
11/4
05:23 pm
tvtx
Travere Therapeutics to Participate at Upcoming Investor Conferences
Low
Report
Travere Therapeutics to Participate at Upcoming Investor Conferences
11/4
11:54 am
tvtx
Travere Therapeutics (NASDAQ:TVTX) had its price target raised by analysts at Piper Sandler from $26.00 to $35.00. They now have a "neutral" rating on the stock.
Low
Report
Travere Therapeutics (NASDAQ:TVTX) had its price target raised by analysts at Piper Sandler from $26.00 to $35.00. They now have a "neutral" rating on the stock.
11/1
10:33 pm
tvtx
Top 2% Travere Catapults To Profit-Taking Zone After Screaming Up Another Beat [Yahoo! Finance]
Low
Report
Top 2% Travere Catapults To Profit-Taking Zone After Screaming Up Another Beat [Yahoo! Finance]
11/1
03:11 pm
tvtx
Travere Therapeutics (TVTX) Hits Fresh High on Impressive Earnings, Bullish Outlook [Yahoo! Finance]
Low
Report
Travere Therapeutics (TVTX) Hits Fresh High on Impressive Earnings, Bullish Outlook [Yahoo! Finance]
11/1
08:33 am
tvtx
Travere Therapeutics (TVTX) Is Up 25.3% After FILSPARI Drives Q3 Profit Turnaround and Global Milestone [Yahoo! Finance]
Low
Report
Travere Therapeutics (TVTX) Is Up 25.3% After FILSPARI Drives Q3 Profit Turnaround and Global Milestone [Yahoo! Finance]
10/31
11:27 pm
tvtx
Travere Therapeutics (TVTX): Unprofitable But Forecast 67% Annual Earnings Growth Challenges Bearish Narratives [Yahoo! Finance]
Low
Report
Travere Therapeutics (TVTX): Unprofitable But Forecast 67% Annual Earnings Growth Challenges Bearish Narratives [Yahoo! Finance]
10/31
02:43 pm
tvtx
Travere Therapeutics (NASDAQ:TVTX) had its price target raised by analysts at TD Cowen from $30.00 to $40.00. They now have a "buy" rating on the stock.
Low
Report
Travere Therapeutics (NASDAQ:TVTX) had its price target raised by analysts at TD Cowen from $30.00 to $40.00. They now have a "buy" rating on the stock.
10/31
11:20 am
tvtx
Travere Therapeutics (NASDAQ:TVTX) had its price target raised by analysts at Citigroup Inc. from $34.00 to $48.00. They now have a "buy" rating on the stock.
Medium
Report
Travere Therapeutics (NASDAQ:TVTX) had its price target raised by analysts at Citigroup Inc. from $34.00 to $48.00. They now have a "buy" rating on the stock.
10/31
11:03 am
tvtx
Travere Therapeutics (NASDAQ:TVTX) had its "buy" rating reaffirmed by analysts at Cowen Inc.
Medium
Report
Travere Therapeutics (NASDAQ:TVTX) had its "buy" rating reaffirmed by analysts at Cowen Inc.
10/30
11:33 pm
tvtx
Travere Therapeutics, Inc. (TVTX) Q3 2025 Earnings Call Transcript [Seeking Alpha]
Low
Report
Travere Therapeutics, Inc. (TVTX) Q3 2025 Earnings Call Transcript [Seeking Alpha]
10/30
04:08 pm
tvtx
Travere Therapeutics Non-GAAP EPS of $0.59 beats by $0.68, revenue of $164.9M beats by $58.81M [Seeking Alpha]
Medium
Report
Travere Therapeutics Non-GAAP EPS of $0.59 beats by $0.68, revenue of $164.9M beats by $58.81M [Seeking Alpha]
10/30
04:01 pm
tvtx
Travere Therapeutics Reports Third Quarter 2025 Financial Results
High
Report
Travere Therapeutics Reports Third Quarter 2025 Financial Results
10/23
04:30 pm
tvtx
Travere Therapeutics to Report Third Quarter 2025 Financial Results
Low
Report
Travere Therapeutics to Report Third Quarter 2025 Financial Results
10/17
09:01 am
tvtx
Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2025
Low
Report
Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2025
10/17
02:10 am
tvtx
Renalys Pharma Reaches Japan PMDA Agreement on Phase III Clinical Trials of Sparsentan for Focal Segmental Glomerulosclerosis (FSGS) and Alport Syndrome (AS) [Yahoo! Finance]
Low
Report
Renalys Pharma Reaches Japan PMDA Agreement on Phase III Clinical Trials of Sparsentan for Focal Segmental Glomerulosclerosis (FSGS) and Alport Syndrome (AS) [Yahoo! Finance]
10/16
06:39 am
tvtx
Travere Therapeutics (NASDAQ:TVTX) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Low
Report
Travere Therapeutics (NASDAQ:TVTX) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.